Skip to main content

Table 4 MCDA outcomes for drug-indication pairs appraised by AHTAPol between 2007 and 2011 (economic criteria included)

From: Potential impact of the implementation of multiple-criteria decision analysis (MCDA) on the Polish pricing and reimbursement process of orphan drugs

No.

Drug-indication pair

Indication uniqueness

Disease rarity

Disease severity

Adv.tech.

Manufacturing technology

Therapeutic alternative

Sci. evid. clin.eff

Benefits from use of medicine

Cost effectiveness

Budget impact

Total number of points

 

THRESHOLD

75 %

         

15 points

1

Nexavar (HCC)

1

2

2

0

2

2

2

0

1

1

13

2

Nplate

2

1

0

2

2

2

1

1

1

1

13

3

Cystadane

2

2

2

0

0

2

0

2

0

2

12

4

Increlex

2

0

0

2

2

2

1

1

0

2

12

5

Revlimid (MM/S)

1

0

2

1

0

2

2

1

1

2

12

6

Yondelis

1

1

2

2

0

2

2

0

1

0

11

7

Somavert

2

1

1

2

2

0

1

1

1

0

11

8

Tasigna

2

2

2

0

0

2

1

1

0

0

10

9

Torisel

1

0

2

2

2

0

1

1

0

1

10

 

THRESHOLD

50 %

         

10 points

10

Vidaza

1

0

2

1

0

0

2

1

1

0

8

11

Atriance

1

0

2

1

0

2

1

0

0

1

8

12

Nexavar (RCC)

1

0

2

0

2

1

2

0

0

0

8

 

THRESHOLD

25 %

         

5 points

  1. Adv. tech. Advancement of technology, Sci. evid. clin. eff. scientific evidence for clinical efficiency, NA no data available, HCC Hepatocellular carcinoma, GIST Malignant gastrointestinal stromal tumors, MM/S Myeloproliferative syndrome, DFSP Dermatofibrosarcoma protuberans, RCC Renal cell carcinoma, MM Multiple myeloma, ALL Ph+ Philadelphia chromosome positive chronic myeloid leukemia, MDS/MPD Myelodysplastic/myeloproliferative diseases